STOCK TITAN
  1. Home
  2. News
  3. CMND

Clearmind Medicine Inc. Common Shares - $CMND STOCK NEWS

Welcome to our dedicated page for Clearmind Medicine Common Shares news (Ticker: $CMND), a resource for investors and traders seeking the latest updates and insights on Clearmind Medicine Common Shares stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Clearmind Medicine Common Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Clearmind Medicine Common Shares's position in the market.

News
Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder
Rhea-AI Summary
Clearmind Medicine Inc. receives approval to commence phase I/IIa clinical trial for alcohol use disorder patients using proprietary psychedelic MEAI-based CMND-100 oral capsule. The trial aims to evaluate safety, pharmacokinetics, and preliminary efficacy in reducing drinking patterns and cravings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
clinical trial
-
News
Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds
Rhea-AI Summary
Clearmind Medicine Inc. submits three patent applications under the PCT for novel psychedelic-derived therapeutics in collaboration with SciSparc Ltd., strengthening its IP portfolio. The company now holds 27 granted patents and 24 pending patent applications across 15 patent families.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.07%
Tags
none
-
News
Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in China
Rhea-AI Summary
Clearmind Medicine Inc. has been granted divisional patent approval by the China National Intellectual Property Administration, expanding its IP protection in the psychedelic space. The company's IP portfolio consists of fifteen utility patent families, including patents and applications in major jurisdictions such as the US, Europe, China, and India. The flagship molecule, MEAI, has shown promising results in regulating binge behaviors and alcohol consumption, offering potential treatment for Alcohol Use Disorder and binge drinking.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.1%
Tags
none
News
Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Center
Rhea-AI Summary
Clearmind Medicine Inc. announced a long-term licensing agreement with BIRAD for innovative cocaine addiction treatment. The agreement secures exclusive rights to the technology, aiming to revolutionize addiction treatment. Positive pre-clinical results for the treatment of cocaine addiction using MEAI were reported, showing potential in abolishing cocaine-induced conditioned place-preference and eliminating heightened craving.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.28%
Tags
none
-
News
Aegis Capital Corp. Acted as Sole Bookrunner on a $2.4 Million Registered Direct and Private Placement for Clearmind Medicine Inc. (NASDAQ: CMND)
Rhea-AI Summary
Aegis Capital Corp. served as the Sole Bookrunner for a $2.4 Million Registered Direct and Private Placement for Clearmind Medicine Inc. (NASDAQ:CMND) on January 16, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.88%
Tags
none
-
News
Clearmind Medicine Inc. Closes US$2.4 Million Registered Direct and Private Placement
Rhea-AI Summary
Clearmind Medicine Inc. announced the closing of definitive agreements with institutional investors for the purchase and sale of Common Shares and Pre-Funded Warrants, raising approximately $2.4 million in gross proceeds. The Company plans to use the net proceeds for general corporate purposes and working capital. Aegis Capital Corp. acted as Exclusive Placement Agent for the offerings, and the registered direct offering was made pursuant to an effective shelf registration statement previously filed with the SEC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.88%
Tags
none
News
Clearmind Medicine Inc. Announces Pricing of $2.4 Million Registered Direct and Private Placement
Rhea-AI Summary
Clearmind Medicine Inc. (NASDAQ: CMND) has entered into definitive agreements with institutional investors for the purchase and sale of Common Shares and pre-funded warrants in a registered direct offering, with aggregate gross proceeds expected to be approximately $2.4 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-43%
Tags
none
-
News
Clearmind Medicine Completed Type A Meeting with the FDA
Rhea-AI Summary
Clearmind Medicine Inc. (CMND) completes Type A meeting with FDA for its proprietary MEAI-based, CMND-100 compound to treat Alcohol Use Disorder (AUD). The meeting aimed to align on the content of the IND resubmission and advance the U.S. regulatory process. The active ingredient, MEAI, has shown promise in reducing alcohol consumption and providing a euphoric alcohol-like experience by interacting with serotonergic and alpha-2-adrenergic receptors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
41.55%
Tags
none
-
News
Clearmind Medicine and SciSparc Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic- Based Treatments
Rhea-AI Summary
Clearmind Medicine Inc. (CMND) collaborates with SciSparc Ltd. (SPRC) to file six US patent applications for novel combinations of psychedelics with PEA. The collaboration aims to develop transformative medicines for mental health disorders and strengthen Clearmind's IP portfolio in the psychedelic space.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.51%
Tags
none
News
Clearmind Medicine Announces It Is In Compliance with All Applicable Nasdaq Listing Standards
Rhea-AI Summary
Clearmind Medicine Inc. (Nasdaq: CMND, CSE: CMND, FSE: CWY) has regained compliance with the minimum bid price requirement set forth by Nasdaq, ensuring that its common shares will continue to be listed and traded on Nasdaq.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
none
Stock CMND logo
Clearmind Medicine Inc. Common Shares

Nasdaq:CMND

CMND Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

CMND Stock Data

4.83M
3.21M
5.48%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States of America
Vancouver